NCT06261541View on ClinicalTrials.gov

Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions
Multiple Sclerosis
Interventions
DEVICE

ABLE Exoskeleton

Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.

Trial Locations (1)

Unknown

Fundación Esclerosis Múltiple Madrid (FEMM), Madrid

All Listed Sponsors
collaborator

Fundación Esclerosis Múltiple Madrid (FEMM)

UNKNOWN

lead

ABLE Human Motion S.L.

INDUSTRY

NCT06261541 - Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting | Biotech Hunter | Biotech Hunter